Citations

Clear

512 citation(s) found for "Turner, ST".

Genomic Association Analysis Suggests Chromosome 12 Locus Influencing Antihypertensive Response to Thiazide Diuretic
Bailey, Kent R. , Chapman, Arlene B. , Schwartz, Gary L. , Chai, High Seng, Sicotte, Hugues , Kocher, Jean‐Pierre , Rodin, Andréi S. , Boerwinkle, Eric , Turner, Stephen T. , Fridley, Brooke L. , Chapman, Arlene B.

Mayo Clinic

Hypertension | July 1, 2008 | Volume: 52 | Issue: 2 | Pages: 359-365

10.1161/hypertensionaha.107.104273 | PMID 18591461 Get It

We conducted a genome-wide association study to identify novel genes influencing diastolic blood pressure (BP) response to hydrochlorothiazide, a commonly prescribed thiazide diuretic preferred for the treatment of high BP. Affymetrix GeneChip Human Mapping 100K Arrays were used to measure single nucleotide polymorphisms across the 22 autosomes in 194 non-Hispanic black subjects and 195 non-Hispanic white subjects with essential hypertension selected from opposite tertiles of the race- and sex-specific distributions of age-adjusted diastolic BP response to hydrochlorothiazide (25 mg daily, PO, for 4 weeks). The black sample consisted of 97 “good” responders (diastolic BP response [mean±SD]=−18.3±4.2 mm Hg; age=47.1±6.1 years; 51.5% women) and 97 “poor” responders (diastolic BP response=−0.18±4.3; age=47.4±6.5 years; 51.5% women). Haplotype trend regression identified a region of chromosome 12q15 in which haplotypes constructed from 3 successive single nucleotide polymorphisms (rs317689, rs315135, and rs7297610) in proximity to lysozyme ( LYZ ), YEATS domain containing 4 ( YEATS4 ), and fibroblast growth receptor substrate 2 ( FRS2 ) were significantly associated with diastolic BP response (nominal P =2.39×10 −7 ; Bonferroni corrected P =0.024; simulated experiment-wise P =0.040). Genotyping of 35 additional single nucleotide polymorphisms selected to “tag” linkage disequilibrium blocks in these genes provided corroboration that variation in LYZ and YEATS4 was associated with diastolic BP response in a statistically independent data set of 291 black subjects and in the sample of 294 white subjects. These results support the use of genome-wide association analyses to identify novel genes influencing antihypertensive drug responses.
Bone Growth and Turnover in Progesterone Receptor Knockout Mice
Rickard, David J., Evans, Glenda L., Hefferan, Theresa E., Hunter, Jamie C., Waters, Katrina M. , O’Malley, Bert W. , Khosla, Sundeep , Spelsberg, Thomas C., Turner, Russell T. , Iwaniec, Urszula T. , Lydon, John P. , Khosla, Sundeep

Mayo Clinic

Endocrinology | February 14, 2008 | Volume: 149 | Issue: 5 | Pages: 2383-2390

10.1210/en.2007-1247 | PMID 18276762 Get It

Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
Smedby, Karin E. , Vajdic, Claire M. , Falster, Michael O. , Martı́nez-Maza, Otoniel , Turner, Jennifer , Hjalgrim, Henrik , Vineis, Paolo , Costantini, Adele Seniori , Bracci, Paige M. , Holly, Elizabeth A., Willett, Eleanor V., Spinelli, John J., Vecchia, Carlo La , Zheng, Tongzhang, Becker, Nikolaus, Sanjosé, Sílvia de , Maso, Luigino Dal , Cocco, Pierluigi , Foretová, Lenka , Staines, Anthony , Brennan, Paul , Severson, Richard K., Cerhan, James R. , Breen, Elizabeth C. , Birmann, Brenda M. , Grulich, Andrew E. , Kane, Eleanor , Engels, Eric A. , Chiu, Brian C.‐H. , Maynadié, Marc , Davis, Scott , Cozen, Wendy , Cerhan, James R , Turner, Jennifer , Cocco, Pierluigi , Vajdic, Claire M , Kane, Eleanor , Martínez-Maza, Otoniel , Birmann, Brenda M

Mayo Clinic

Blood | February 8, 2008 | Volume: 111 | Issue: 8 | Pages: 4029-4038

10.1182/blood-2007-10-119974 | PMID 18263783 Get It

Abstract Some autoimmune disorders are increasingly recognized as risk factors for non-Hodgkin lymphoma (NHL) overall, but large-scale systematic assessments of risk of NHL subtypes are lacking. We performed a pooled analysis of self-reported autoimmune conditions and risk of NHL and subtypes, including 29 423 participants in 12 case-control studies. We computed pooled odds ratios (OR) and 95% confidence intervals (CI) in a joint fixed-effects model. Sjögren syndrome was associated with a 6.5-fold increased risk of NHL, a 1000-fold increased risk of parotid gland marginal zone lymphoma (OR = 996; 95% CI, 216-4596), and with diffuse large B-cell and follicular lymphomas. Systemic lupus erythematosus was associated with a 2.7-fold increased risk of NHL and with diffuse large B-cell and marginal zone lymphomas. Hemolytic anemia was associated with diffuse large B-cell NHL. T-cell NHL risk was increased for patients with celiac disease and psoriasis. Results for rheumatoid arthritis were heterogeneous between studies. Inflammatory bowel disorders, type 1 diabetes, sarcoidosis, pernicious anemia, and multiple sclerosis were not associated with risk of NHL or subtypes. Thus, specific autoimmune disorders are associated with NHL risk beyond the development of rare NHL subtypes in affected organs. The pattern of associations with NHL subtypes may harbor clues to lymphomagenesis.
New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancer: Summary Statement from 2007 Santa Monica Conference
Rosen, Lee S. , Bilchik, Anton J. , Beart, Robert W., Benson, Al B. , Chang, Kenneth J. , Compton, Carolyn C. , Haller, Daniel G. , Ko, Clifford Y. , Lynch, Patrick M. , Nelson, Heidi , Stamos, Michael J. , Turner, Roderick R., Willett, Christopher G. , Grothey, Axel

Mayo Clinic

Clinical Cancer Research | November 15, 2007 | Volume: 13 | Issue: 22 | Pages: 6853s-6856s

10.1158/1078-0432.ccr-07-1629 | PMID 18006789 Get It

Abstract The 2007 Santa Monica Conference on Assessing and Treating Early-Stage Colon and Rectal Cancer, a multidisciplinary meeting of leaders in surgery, medical and radiation oncology, and pathology, was convened on January 12 to 13, 2007. The purpose of the meeting was to assess current data and issues in the field and to develop recommendations for advancing patient care and clinical research. Topics included pathologic assessment and staging, transanal versus laparoscopic versus open resection, adjuvant therapy, genetic testing and counseling, cooperative group strategies, and the use of biological therapies and novel agents. A review of the key issues discussed, as well as conclusions and recommendations considered significant to the field, is summarized below and presented at greater length in the individual manuscripts and accompanying discussion that comprise the full conference proceedings. Although the management of early-stage colon and rectal cancers remains a challenge for all of us, the development and use of new technologies and methods of assessment and treatment over the past several decades is yielding encouraging results. A variety of opportunities to further improve outcomes were addressed in this forum, including recommendations that specific protocols be adopted regarding surgical and pathologic dissection and reporting, particularly for stage II disease; the corollary need to increase active multidisciplinary collaboration; and the development of comprehensive consensus guidelines and recommendations to standardize care in early-stage colorectal cancer.
2-Methoxyestradiol Suppresses Osteolytic Breast Cancer Tumor Progression In vivo
Cicek, Muzaffer, Goblirsch, Michael , Vrabel, Anne M., Ruan, Ming, Clohisy, Denis R., Turner, Russell R., Oursler, Merry Jo, Iwaniec, Urszula T.

Mayo Clinic

Cancer Research | November 1, 2007 | Volume: 67 | Issue: 21 | Pages: 10106-10111

10.1158/0008-5472.can-07-1362 | PMID 17974950 Get It

Abstract 2-Methoxyestradiol (2ME2), a physiologic metabolite of 17β-estradiol (estrogen), has emerged as a promising cancer therapy because of its potent growth-inhibitory and proapoptotic effects on both endothelial and tumor cells. 2ME2 also suppresses osteoclast differentiation and induces apoptosis of mature osteoclasts, and has been shown to effectively repress bone loss in an animal model of postmenopausal osteoporosis. Given these observations, we have examined whether 2ME2 could effectively target metastasis to bone, osteolytic tumors, and soft tissue tumors. A 4T1 murine metastatic breast cancer cell line was generated that stably expressed Far Red fluorescence protein (4T1/Red) to visualize tumor development and metastasis to bone. In an intervention study, 4T1/Red cells were injected into bone marrow of the left femur and the mammary pad. In the latter study, 2ME2 (10, 25, and 50 mg/kg/d) treatment began on the same day as surgery and was continued for the 16-day duration of study. Tumor cell growth and metastasis to bone were monitored and bone volume was determined by micro-computed tomography. 2ME2 inhibited tumor growth in soft tissue, metastasis to bone, osteolysis, and tumor growth in bone, with maximum effects at 50 mg/kg/d. Furthermore, tumor-induced osteolysis was significantly reduced in mice receiving 2ME2. In vitro, 2ME2 repressed osteoclast number by inducing apoptosis of osteoclast precursors as well as mature osteoclasts. Our data support the conclusion that 2ME2 could be an important new therapy in the arsenal to fight metastatic breast cancer. [Cancer Res 2007;67(21):10106–11]
Association of Plasma Resistin With Glomerular Filtration Rate and Albuminuria in Hypertensive Adults
Ellington, Allison A., Malik, A. Rauoof , Klee, George G., Turner, Stephen T. , Rule, Andrew D. , Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

Hypertension | September 5, 2007 | Volume: 50 | Issue: 4 | Pages: 708-714

10.1161/hypertensionaha.107.095257 | PMID 17785630 Get It

Resistin, a recently discovered proinflammatory cytokine, has been variably associated with insulin resistance, inflammation, and renal dysfunction. We investigated the association of plasma resistin with estimated glomerular filtration rate and albuminuria in 1575 hypertensive adults without known coronary heart disease or stroke (857 blacks and 718 non-Hispanic whites). Resistin was measured by a solid phase sandwich immunoassay, estimated glomerular filtration rate was estimated from serum creatinine, and albuminuria was expressed as urine albumin:creatinine ratio. After adjustment for coronary heart disease risk factors (age, sex, body mass index, smoking history, systolic blood pressure, diabetes, and total and high-density lipoprotein cholesterol) and use of renin-angiotensin blockers and statins, higher plasma resistin levels were associated with lower estimated glomerular filtration rate in both ethnic groups (each P <0.0001); the association remained significant after further adjustment for a marker of insulin resistance (homeostasis model assessment for insulin resistance) and a marker of inflammation (plasma C-reactive protein) and was seen in subjects with and without diabetes (each P <0.0001) in both ethnic groups. Higher plasma resistin levels were associated with a higher urine albumin:creatinine ratio in black subjects with diabetes ( P <0.0001) and non-Hispanic white subjects with diabetes ( P =0.032), independent of coronary heart disease risk factors, hypertension medication use, and statin use; the association remained significant after additional adjustment for homeostasis model assessment for insulin resistance and C-reactive protein. In adults with hypertension, higher circulating resistin levels were associated with a lower estimated glomerular filtration rate and with increased urine albumin:creatinine ratio in the presence of concomitant diabetes. This association was independent of coronary heart disease risk factors and markers of insulin resistance and inflammation.
MRI Findings of 26 Patients with Parsonage-Turner Syndrome
Scalf, Richard E., Wenger, Doris E. , Frick, Matthew A., Mandrekar, Jayawant N. , Adkins, Mark C.

Mayo Clinic

American Journal of Roentgenology | June 19, 2007 | Volume: 189 | Issue: 1 | Pages: W39-W44

10.2214/ajr.06.1136 | PMID 17579134 Get It

Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein
Parkin, Edward T. , Watt, Nicole T. , Hussain, Ishrut, Eckman, Elizabeth A. , Eckman, Christopher B., Manson, Jean , Baybutt, Herbert, Turner, Anthony J. , Hooper, Nigel M.

Mayo Clinic

Proceedings of the National Academy of Sciences | June 16, 2007 | Volume: 104 | Issue: 26 | Pages: 11062-11067

10.1073/pnas.0609621104 | PMID 17573534 Get It

Proteolytic processing of the amyloid precursor protein (APP) by β-secretase, β-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid β (Aβ) peptide, which is involved in the pathogenesis of Alzheimer's disease. The normal cellular function of the prion protein (PrP C ), the causative agent of the transmissible spongiform encephalopathies such as Creutzfeldt–Jakob disease in humans, remains enigmatic. Because both APP and PrP C are subject to proteolytic processing by the same zinc metalloproteases, we tested the involvement of PrP C in the proteolytic processing of APP. Cellular overexpression of PrP C inhibited the β-secretase cleavage of APP and reduced Aβ formation. Conversely, depletion of PrP C in mouse N2a cells by siRNA led to an increase in Aβ peptides secreted into the medium. In the brains of PrP knockout mice and in the brains from two strains of scrapie-infected mice, Aβ levels were significantly increased. Two mutants of PrP, PG14 and A116V, that are associated with familial human prion diseases failed to inhibit the β-secretase cleavage of APP. Using constructs of PrP, we show that this regulatory effect of PrP C on the β-secretase cleavage of APP required the localization of PrP C to cholesterol-rich lipid rafts and was mediated by the N-terminal polybasic region of PrP C via interaction with glycosaminoglycans. In conclusion, this is a mechanism by which the cellular production of the neurotoxic Aβ is regulated by PrP C and may have implications for both Alzheimer's and prion diseases.
Coronary Artery Calcification Progression Is Heritable
Cassidy‐Bushrow, Andrea E. , Bielak, Lawrence F. , Sheedy, Patrick F. , Peyser, Patricia A. , Turner, Stephen T. , Kullo, Iftikhar J. , Lin, Xihong

Mayo Clinic

Circulation | June 12, 2007 | Volume: 116 | Issue: 1 | Pages: 25-31

10.1161/circulationaha.106.658583 | PMID 17562953 Get It

Background— Coronary artery calcification (CAC), a marker of coronary artery atherosclerosis, can be measured accurately and noninvasively with the use of electron beam computed tomography. Serial measures of CAC quantify progression of calcified coronary artery plaque. Little is known about the role of genetic factors in progression of CAC quantity. Methods and Results— We quantified the relative contributions of measured risk factors and unmeasured genes to CAC progression measured by 2 electron beam computed tomography examinations an average of 7.3 years apart in 877 asymptomatic white adults (46% men) from 625 families in a community-based sample. After adjustment for baseline risk factors and CAC quantity, the estimated heritability of CAC progression was 0.40 ( P <0.001). Baseline risk factors and CAC quantity explained 64% of the variation in CAC progression. Thus, genetic factors explained 14% of the variation [(100−64)×(0.40)] in CAC progression. After adjustment for risk factors, the estimated genetic correlation (pleiotropy) between baseline CAC quantity and CAC progression was 0.80 and was significantly different than 0 ( P <0.001) and 1 ( P =0.037). The environmental correlation between baseline CAC quantity and CAC progression was 0.42 and was significantly different than 0 ( P =0.006). Conclusions— Evidence was found that many but not all genetic factors influencing baseline CAC quantity also influence CAC progression. The identification of common and unique genetic influences on these traits will provide important insights into the genetic architecture of coronary artery atherosclerosis.
The Compartments of the Foot: A 3-Tesla Magnetic Resonance Imaging Study with Clinical Correlates for Needle Pressure Testing
Reach, John S., Amrami, Kimberly K. , Felmlee, Joel P. , Stanley, David , Alcorn, Joseph, Turner, Norman S.

Mayo Clinic

Foot & Ankle International | June 8, 2007 | Volume: 28 | Issue: 5 | Pages: 584-594

10.3113/fai.2007.0584 | PMID 17559766 Get It

Background: Reliable measurement of subfascial pressures represents an essential part of compartment syndrome management. To date, there is neither consensus on the number or location of foot compartments, nor a standardized protocol for needle placement. The purpose of this study was to devise a new system using 3-Tesla MRI that assesses the number and location of these compartments. Methods: To document the specific location of foot compartments, high resolution 3-Tesla MRI (General Electric, Milwaukee, WI) was coupled with a dedicated transmit-receive high signal-to-noise foot/ankle coil (IGC-Medical Advances, Milwaukee, WI). Individual compartments were highlighted and mapped to T1-weighted MRI. Three-dimensional image analysis allowed standardized needle placement recommendations. Results: Six feet from healthy volunteers were imaged. From these, ten compartments were described: (1) medial, (2) central superficial, (3) central deep (adductor), (4) lateral, (5–8) interossei, (9) calcaneal, and (10) skin. Optimal needle placement and depth were identified. Conclusions: The proposed system allowed us to assess the number and location of foot compartments. Computer image analysis enabled us to define exact points for needle insertion and depth of penetration for accurate pressure monitoring.